Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a flash of light beat a blinding eye infection?

NCT ID NCT07743489

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 04, 2026 · Last updated Aug 18, 2026 · Updated 3 times

Summary

This study tests whether a light-activated treatment called Rose Bengal photodynamic therapy can help people with a severe fungal eye infection called Fusarium keratitis. The infection can cause vision loss, and standard treatments may not always work. Participants receive either the active light therapy or a sham procedure, and their vision is checked after three months. The goal is to see if this approach can clear the infection and improve visual outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Rose Bengal photodynamic therapy (RB-PDT), a light-activated treatment applied to the cornea
What this could lead to
If effective, this could offer a new way to treat Fusarium keratitis, potentially saving vision and reducing the need for more invasive procedures.
What could go wrong
The trial is still in progress, and results may not confirm benefit. Risks include possible discomfort, corneal damage, or lack of improvement over standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 434 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2027

An estimate. Start dates often move.

Expected to finish

Jan 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Presence of culture positive fusarium fungal keratitis * Age over 18 years * Moderate to severe vision loss, defined as Snellen visual acuity of 20/40 (6/12) to 20/400 (6/120) * Corneal thickness ≥350 µm, as measured on AS-OCT * Basic understanding of the study as determined by the physician * Commitment to return for follow up visits Exclusion Criteria: * History of hypersensitivity to Rose Bengal * Evidence of concomitant infection on exam, gram stain, or confocal microscopy (i.e. herpes, both bacteria and acanthamoeba on gram stain) * History of intraocular surgery within the last three months\* * Impending or frank perforation at recruitment * Involvement of sclera at presentation * Presence of desmestocele at recruitment * Non-infectious or autoimmune keratitis * History of corneal transplantation * Pinhole visual acuity worse than 20/200 in the unaffected eye * Participants who are decisionally and/or cognitively impaired

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Fusarium keratitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    4 sites in 3 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Aravind Eye Care System

    Madurai, Tamil Nadu, 625 020, India

  • Federal University of São Paulo

    São Paulo, 04023-062, Brazil

  • Stanford University

    Palo Alto, California, 94303, United States

  • University of Miami - Bascom Palmer Eye Institute

    Miami, Florida, 33136, United States